Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Roundtable discussion on the latest advances in multiple myeloma therapy

ASH 2009

Published: 2 Mar 2010

Views: 10101

Rating:

Save

Prof Gordon McVie, Prof Thierry Facon, Prof Meletios Dimopoulos, Prof Heinz Ludwig

Experts in haematology-oncology discuss the latest developments in multiple myeloma therapy, including highlights from ASH 2009. The discussion focuses on the evolving role of novel agents in the treatment of multiple myeloma, and how this translates to clinicians practice.

Supported by an unrestricted educational grant from Janssen-Cilag and HCA Cancer Care

Categories:
Haematology oncology

Related Videos

Linvoseltamab induces deep and durable responses in patients with relapsed or...

Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA

$Linvoseltamab induces deep and durable responses in patients with relapsed or refractory multiple myeloma ( Dr Sundar Jagannath - Icahn School of Medicine at Mount Sinai, New York, USA )$

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and...

Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects ( Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal )

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma...

Dr Jonathan Friedberg - University of Rochester, Rochester, USA

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituximab therapy ( Dr Jonathan Friedberg - University of Rochester, Rochester, USA )

Management of multiple myeloma in a resource-constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Management of multiple myeloma in a resource-constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Significant clinical benefits observed with revumenib monotherapy in relapsed...

Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA

$Significant clinical benefits observed with revumenib monotherapy in relapsed/refractory KMT2Ar acute leukaemia ( Dr Ibrahim Aldoss - City of Hope National Medical Center, Duarte, USA )$

Ide-cell enhances health-related quality of life for refractory multiple myeloma

Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium

$Ide-cell enhances health-related quality of life for refractory multiple myeloma ( Dr Michel Delforge - University Hospital Leuven, Leuven, Belgium )$

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B...

Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany

Adding nivolumab to R-GemOx shows enhanced efficacy in treating R/R large B-cell lymphoma ( Dr Gerhard Held - Westpfalz-Klinikum, Kaiserslautern, Germany )

More from ecancer